25 Nov 2015

Globes – Teva invests $10m in UK co’s migraine treatment

Teva says Heptares’s development complements its own migraine candidate TEV-48125, considered a potential blockbuster.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and UK-based Heptares Therapeutics, a unit of Sosei Group Corporation (TSE Mothers Index: 4565) have announced a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.